<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.taxtmi.com/rss_sitemap/rss_feed_blog.xsl?v=1750492856"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Veeda Group Rebrands as &#039;Veeda Lifesciences&#039;</title>
    <link>https://www.taxtmi.com/news?id=29346</link>
    <description>Veeda Clinical Research Limited proposes a public issue and intends to file a draft red herring prospectus with the securities regulator subject to approvals and market conditions; the company states securities may not be offered or sold in certain foreign jurisdictions absent registration or an exemption, and any foreign offering will be made via a prospectus containing detailed company and financial information.</description>
    <language>en-us</language>
    <pubDate>Thu, 02 Jan 2025 15:31:03 +0530</pubDate>
    <lastBuildDate>Thu, 02 Jan 2025 15:31:03 +0530</lastBuildDate>
    <generator>TaxTMI RSS Generator</generator>
    <atom:link href="https://www.taxtmi.com/rss_feed_blog?id=785943" rel="self" type="application/rss+xml"/>
    <item>
      <title>Veeda Group Rebrands as &#039;Veeda Lifesciences&#039;</title>
      <link>https://www.taxtmi.com/news?id=29346</link>
      <description>Veeda Clinical Research Limited proposes a public issue and intends to file a draft red herring prospectus with the securities regulator subject to approvals and market conditions; the company states securities may not be offered or sold in certain foreign jurisdictions absent registration or an exemption, and any foreign offering will be made via a prospectus containing detailed company and financial information.</description>
      <category>News</category>
      <law>-</law>
      <pubDate>Thu, 02 Jan 2025 15:31:03 +0530</pubDate>
      <guid isPermaLink="true">https://www.taxtmi.com/news?id=29346</guid>
    </item>
  </channel>
</rss>